Posted by AGORACOM-JC
at 4:24 PM on Thursday, December 30th, 2021
FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.
More than just lip service, FOBI AI is firing on all cylinders. Here are just some of the highlights from December:
Review confirms Q by SoLVBL’s security, reliability and operational excellence, while reducing overall operational workload risks for cloud-based applications.
The Functional Technical Review (“FTR”) also confirmed the speed and functionality of Q by SoLVBLTM, as well as providing SoLVBL with data required to develop a cost model.
This successful trial, with all objectives achieved, will enhance SoLVBL’s continuing marketing and sales efforts.
SoLVBL Solutions and Empower Clinics Sign Memorandum of Understanding (MoU) to Develop a Program for Data Security in Diagnostic Testing
“We are excited to collaborate with SoLVBL Solutions, a company with broad know-how in data verification and cybersecurity. The collaboration agreement entered with Empower combines SoLVBL Solutions’ data verification capabilities with Empower’s experience and extensive expertise in the design, construction, operation, and maintenance of healthcare clinics and world-class diagnostic laboratories. With the increase in data collection, the demand to protect and verify data is unprecedented. We have seen such announcements come from both the Canadian and American governments. We feel this verification solution will allow us to continue to grow and meet the demands and needs of our patients and health care administrations. The collaboration aligns with our expansion and growth plans to become a global technological leader in the healthcare diagnostic sector.” said Steven McAuley, CEO of Empower.
Data Security Today
We live in a digital data age
Data is critical for the present and future of automation, AI, IoT, analytics etc.
As decisions become more automated, data integrity becomes even more crucial
The cyber security market size was valued at $149.67 billion in 2019 and is projected to reach $304.91 billion by 2027
North America accounts for 45% of market
Data Forgery
Data is the “new gold”
Forgery, hacking is a growing problem in the data world.
In a world increasingly reliant upon more and faster data for automated decision-making, operational efficiency and competitive advantage, data integrity and protection is critical to ensure a client’s data is not a liability.
Solving the problem
In the physical world fraud can be detected by using physical tools to detect alterations, such as hand writing analysis, watermarks, age of paper etc. In the digital world, which comprises of 1’s and 0’s, there is no way of knowing if the 1’s and 0’s have been altered, unless you use Q by SoLVBL.
Q by SoLVBL
So… what technology does this replace?
Q by SoLVBL™ operates dramatically faster and at lower latency than the alternative today, Digital Ledger Technology (DLT)—commonly referred to as Blockchain. This in turn enables data uses and applications DLT does not support.
The Q by SoLVBL™ protocol produces a unique digital seal for each submitted record.
What can this technology be used for?
Link the record to the possessor of a private signing key, i.e. an identity
Determine relative ordering of records sealed in this manner
Uniquely identify an instance of the record by way of its seal (each seal reflects an instance)
Is Q by SoLVBL™ difficult / expensive to implement? Or is it an add-on?
Cost-effective to implement
May be integrated with existing application in a straightforward manner, wherever data is created, stored or used.
Whether Q by SoLVBL™ is applied as an add-on or technology replacement depends on the architecture needs and maturity of the system in which it is used.
Who are the company’s competitors?
Users seeking such assurances will typically gravitate towards various Blockchain or Distributed Ledger Technologies (DLT).
Significant shortcoming of DLT is that the inherently decentralized nature of these technologies causes them to impose prohibitive latency or bandwidth limitations on their users.
Q by SoLVBL™ can process 150,000 transactions per second at a minimum, and millions per second depending upon the application.
Our Vision “Our dream is a world in which every digital record’s authenticity can be established quickly and irrefutably to create trust fast.”
Our Mission “To empower better, faster decisions by developing a universal standard for establishing digital record authenticity which is easy to adopt, cheap to use, offers cryptographic assurances, and will not bottleneck systems.”
**
WHY SOLVBL
SoLVBL’s innovative integrity solutions give clients and customers added trust to ensure their data is an asset
Cost of data security is significant
The finance and insurance sector were the most- attacked industry in 2019, with retail payments second
Data security & privacy segment expected to outpace total cyber security growth
Data is valuable and important. Should be asset not liability
Highlights
– Q by SoLVBL is a cryptographically verified, patented, best-in-class cybersecurity product;
– Q by SoLVBL is simple to use;
– Enhanced confidentiality, by never needing to see your data;
– It is compatible with existing systems, so no expensive hardware/software updates;
– Q by SoLVBL is fast. Q can process in excess of 150,000 transactions/second; and
– Our Software as a Service (SaaS) model is very cost effective to the client.
– SoLVBL announces first Memorandum of Understanding (MoU) in the Financial Services Sector, with QuantGate Systems to Develop a Program for Data Security
– Allow to further demonstrate its capabilities around data security and speed of transactions
Salt Lake City Clinic welcomes incoming addictions specialist, Dr. Amy de la Garza
We are pleased to announce the opening of a new clinic located in downtown Salt Lake City (SLC). In addition to Novamind’s suite of mental health treatments, the SLC Clinic specializes in integrative behavioural health and services for adults with substance use disorders (SUD) led by incoming Medical Director, Dr. Amy de la Garza.
The SLC Clinic’s outpatient SUD services provide an alternative to residential treatment programs and work to address the highly complex public health crisis that is worsening alongside challenges related to access. In 2020 alone, 93,000 Americans died of a drug overdose-an increase of 30 per cent from the previous year, according to the Centers for Disease Control and Prevention.
Dr. Reid Robison, Novamind’s Chief Medical Officer, commented: “Social isolation and despair related to the COVID-19 pandemic have further fueled a significant increase in substance use disorders and related deaths. Dr. de la Garza’s expertise in addiction medicine and behavioural health is a vital addition to our team as we continue to expand Novamind’s clinic footprint to address unmet need and broaden our innovative, evidence-based treatments.”
Dr. de la Garza is a board-certified family practice physician with 10 years of experience providing specialized care for patients with behavioral health and SUD diagnoses. She earned her Doctorate in Medicine from the University of Colorado before completing a Family Medicine Residency at the Utah Healthcare Institute. She also completed an Addiction Medicine Fellowship at the University of Utah and is an Institute for Functional Medicine Certified Practitioner. In 2017, Dr. de la Garza opened the first community-based, co-located primary care and behavioral health practice in Salt Lake City, Utah.
“I am thrilled to join Novamind and look forward to establishing an innovative outpatient substance use disorder program that brings together addiction and integrative medicine and treats the whole person,” said Dr. de la Garza, who is also trained in integrative modalities and lifestyle medicine, including nutrition, movement, sleep, stress management and social connection.
Novamind will collect clinical data on the efficacy of the integrative treatment approach for SUD and host upcoming studies for conditions like opioid use disorder. Additionally, the SLC Clinic will pilot an innovative and cost-effective group medical visit model that has been shown to reduce anxiety and depression, as well as improve outcomes in chronic conditions like cardiovascular disease and diabetes.
The SLC Clinic is located at 807 E South Temple, Suite 101, Salt Lake City, Utah.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore anxiety. They discuss the following topics and much more: • What is an anxiety disorder? • Anxiety management skills • The role of medicines in treating anxiety
Utah Business covers Dr. Reid Robison and the success of ketamine-assisted psychotherapy in our clinics. “While it’s still early and much more testing is to be done, Robison describes what’s happening in mental health care as a ‘psychedelic renaissance’.”
Dr. Reid Robison, Matt Johnson and Robin Carhart-Harris discuss The Science of Psychedelics: Therapeutic mechanisms and clinical outcomes for a range of mental illnesses and other conditions.
Chief Medical Officer Dr. Reid Robison’s keynote presentation at the Mind Medicine Australia International Summit on Psychedelic Therapies for Mental Illness.
“While the U.S. has been battling Covid-19 it’s gotten lost in the shuffle that the nation had record numbers of drug overdose-related deaths in 2020; approximately 93,000. In addition, from May 2020 through April 2021, the figure rises to 100,000.” We need better treatment options for people with substance use disorders (SUD). It’s the driving force behind why incoming Novamind Medical Director Dr. Amy de la Garza will lead SUD programming at our new Salt Lake City clinic.
We are currently in a mental health crisis. Depression, anxiety and symptoms of PTSD have run rampant over the last two years, accelerated by the COVID-19 pandemic and its far-reaching effects. The need for new and effective mental health treatments has never been clearer. We have seen the efficacy of ketamine-assisted psychotherapy firsthand. And we are eager to continue psychedelic research. If you’d like to stay up to date on upcoming studies hosted by Novamind, visit us here and get in touch. “So what else does the future hold for psychedelics? For one thing, taking psychedelics could one day be the same as taking an everyday pill prescribed by your doctor.”
Posted by AGORACOM-JC
at 5:48 PM on Thursday, December 9th, 2021
Kidoz (KIDZ: TSXV) owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
Total Revenue of $2,814,642 – growth of 47% compared to Q3 2020 Total Revenue of $1,919,973 and growth of 29% from revenue of $2,177,505 for the second quarter of 2021.
Gross Profit of $1,226,534 – growth of 34% compared to Q3 2020 Gross Profit of $914,657 and growth of 20% from Gross Profit of $1,024,333 for the second quarter of 2021.
Adjusted EBITDA of $265,984 compared to an adjusted EBITDA of $16,484 for Q2 2021.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss their recently announced Programmatic Solution “Kidoz Connect”.
This new product release is a unique programmatic solution providing ‘review & monetize’ technology to enable open market ad sourcing at scale. Kidoz Connect enables any brand, agency or DSP to programmatically reach the Kidoz unique inventory of over 300 million users accessible in a fully COPPA/GDPR compliant manner, through a single point of integration.
This new technology could increase impressions sold by 3-5X.
Co-CEO Eldad Ben Tora commented,
“Kidoz Connect is currently live with select launch partners and we are actively developing and integrating a number of new sources that will together create the pipeline of programmatic ad campaigns available to Kidoz’s app publisher network. As Kidoz advances its multiple product offerings, new opportunities arise in the bountiful mobile advertising ecosystem that is projected by eMarketer to exceed over US$400 billion by 2023 (eMarketer). Kidoz is perfectly positioned with powerful technology in a booming market and management anticipates a record Q4 and 2022 ahead.”
Now sit back, relax and watch this powerful interview with Co-CEOs of Kidoz Inc.
Posted by AGORACOM-JC
at 5:52 PM on Wednesday, December 8th, 2021
FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.
More than just lip service, these are just a sample of the major milestones reached by $FOBI as of the end of November:
293% Increase In First Quarter Revenue
Signed Agreement With Caddle, Canada’s Largest Mobile-First Insights Marketplace App To Target And Engage CPG Brands and Grocery Retailers
Signed Deal to Provide Digital Vaccination and Testing Verification Solution for Sammy Hagar’s Sold Out Shows at The STRAT Hotel, Casino & SkyPod in Las Vegas
Signed CheckVax(TM) Deal With the University of Nevada, Las Vegas for Men’s and Women’s NCAA Basketball Games
By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now be included in. Fobi will now generate additional revenue through hardware, products and services sold on Amazon Business.
Rob Anson, Fobi CEO stated : “Acquiring Passworks will not only enable us to further accelerate our business strategy as we consolidate the wallet pass industry, but it will also provide us with direct and immediate access to very valuable customers, with additional operational capacity and provide further immediate revenue. This strategic acquisition of Passworks represents another key step for us in terms of achieving our goal of becoming a global mobile Wallet pass leader.”
Sit back, relax and watch this powerful interview with CEO Rob Anson.
Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice
Total revenue of $1,857,750, +113% when compared to same period last year
Total working capital of $6,834,011 to fund operations
“Q1 was a strong start to fiscal year 2022, driven by the addition of another clinic to our network and increased patient demand for our comprehensive range of innovative mental health treatments,” said Yaron Conforti, Novamind’s CEO and Director. “We continue to make progress on our national clinic expansion, most recently with a letter of intent to acquire two locations in Arizona. Our clinical research business has been actively building an exciting pipeline of contracts with leading drug developers.”
“Novamind operates best-in-class psychiatry clinics and clinical research sites, with a proven ability to replicate our clinic model in the U.S. Our agreement with Bienstar is an exciting opportunity to export our clinical expertise and capabilities into international markets,” said Yaron Conforti, Novamind CEO and Director. “Partnering with local operators allows us to disseminate Novamind’s best practices and SOPs globally, with minimal investment and managed risk, ultimately expanding access to psychedelic medicine and innovative mental healthcare on a global scale.”
Novamind’s CEO and Director, Yaron Conforti, will join the Psychedelics Assisted Psychotherapy panel discussion from 1:30 PM to 2:15 PM EST. Mr. Conforti will also deliver a corporate presentation to update investors on recent milestones and progress towards the global expansion of Novamind’s psychedelic clinics and research sites.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the concept of the “middle way” and the need for balance in an increasingly polarized world.
In a piece for The Guardian, psychedelic pioneer Rick Doblin explains how psychedelics can change humanity for the better. “We envision a day when psychedelics will be more than a last-ditch treatment: they will be a catalyst for mass mental health.”
The work to destigmatize psychedelics has been long and arduous. Just ask Rick Doblin. He’s devoted his life to it. But as more and more research comes out, more and more people are changing their opinion on the once villainized substances. “Public attitudes around psychedelics are shifting: A recent Nanos Research survey, commissioned by the Canadian Psychedelic Association, found that 82 per cent of Canadians are in favour of psilocybin-assisted therapy in end-of-life illness, while 78 per cent of those polled support legalizing it to improve the quality of life for palliative and end-of-life patients.”
Posted by AGORACOM-JC
at 4:07 PM on Tuesday, September 21st, 2021
Kidoz (KIDZ: TSXV) owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss the entrance into lucrative teens and parents segment of soon to be $400 BILLION Mobile Ad Market.
We discuss:
New markets
Anticipated growth
Agencies that have already booked
+more
Q2 2021 highlights include:
Total Revenue of $2,177,505 – growth of 196% compared to Q2 2020 Total Revenue of $736,827.
AdTech revenue of $2,120,500 – growth of 247% compared to Q2 2020 AdTech Revenue $611,709.
Gross Profit of $1,024,333 – growth of 214% compared to Q2 2020 Gross Profit of $325,769.
EBITDA of $48,079 a 124% improvement from an EBITDA loss of ($197,057) in Q2 2020.
Sit back, relax and watch this powerful interview.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by returning guest, Vhari Macbeth to discuss psycholytic ketamine-assisted psychotherapy (KAP).
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a clinical trial sponsored by Karuna Therapeutics, Inc., a clinical-stage neuroscience biopharmaceutical company
The phase III study will evaluate the investigational therapy KarXT for the treatment of schizophrenia, a serious and potentially disabling condition affecting approximately 20 million people worldwide.
Dr. Reid Robison, Novamind’s Chief Medical Officer and Principal Investigator at CCR said, “We need more innovation in this field and I’m hopeful to see compounds like KarXT that have new ways of acting on the brain and the potential for improved efficacy and side effect profiles.”
As psychedelics continue to break free from the stigma surrounding them, more and more people are seeing the promise these drugs have in changing the way we treat mental health. “Recent trials are showing that psychedelics are proving not only successful but also incredibly effective when stacked up against traditional forms of treatment, with one recent trial reporting that they are up to four times more effective than antidepressants.”
In a big step forward for psychedelic research, the DEA is set to increase limits for psilocybin. From the DEA: “DEA firmly believes in supporting regulated research of schedule I controlled substances.” We look forward to increased research and have a dedicated psychedelic contract research organization (CRO) in Cedar Clinical Research, capable of studying promising new treatments.
Posted by AGORACOM-JC
at 1:06 PM on Thursday, September 16th, 2021
PyroGenesis $PYR is the world leader in the development of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world that significantly reduce both greenhouse gases and costs of doing business for some of the world’s biggest companies in these following verticals:
Ultra High-Tech 3D Printing (Additive Manufacturing)
Iron Ore Pelletization
Aluminum Smelters Recovery Of Dross
High-Purity Silicon For EV Batteries
….. Military Where Their Tech Sits On 4 US Aircraft Carriers.
Today’s $6 Million Plasma Torch Order Represents 4 Torches From Major Iron Ore Pelletizer Client “B”
“B” expects next orders to be for 130 torches
NPV estimate per torch is now $7M = $910,000,000
Client “A” has already requested a cost estimate for 36 torches
Discussions with Client “C” and many others are also taking place
HOW BIG IS THE OPPORTUNITY?
“The total world pellet production of 400 million metric tonnes of pellets represents a potential market for torch sales in excess of $10B worldwide. For reference, 40 million tonnes of CO 2 represent the combined yearly emissions of 8.7 million US passenger vehicles”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Hannah Cross to discuss how psychedelic-assisted psychotherapy is used to treat trauma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss how ketamine-assisted psychotherapy is used to treat eating disorders
We pleased to announce our common shares have been approved for trading under the ticker symbol “NVMDF” on the OTCQB® Venture Market, a U.S. trading platform operated by the OTC Markets Group, Inc.
“With this listing, we look forward to expanding Novamind’s presence in the U.S. and deepening our relationships with a broad base of institutional and retail investors.” said Yaron Conforti, CEO and Director.
CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.
Learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.
BBC Future covers the experience, culture and future of psychedelics and “what might follow if psychedelics become mainstream.” It’s a popular theme in this week’s roundup: what the world will look like after the psychedelic revolution. “Psychedelics offer something that few other things can: an experience well beyond what our everyday reality could conceive or expect.” With such life changing drugs and therapies becoming available, there’s no doubt the future will look a lot different.
This article delivers more positive news about ketamine and esketamine, which we currently use in our Cedar Psychiatry clinics. Learn more about how we use these powerful drugs here. “Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression, according to a review published online Aug. 5 in the Harvard Review of Psychiatry.”
Rick Doblin and Jennifer Ouyang Altman lay out the potential risks of not having standardized psychedelic education for providers. It’s a problem that will arise as psychedelics continue to move into the mainstream. It’s one reason why education is such a big component of our mission to increase access to psychedelic medicine. On the Psychedelic Therapy Frontiers podcast, we cover topics across the spectrum from trip-sitting to treating trauma with psychedelic-assisted psychotherapy. Another way we’re helping address this issue is by creating psychedelic treatment protocols, sharing best-in-class techniques and procedures with the wider population. Learn more here.
